{
    "organizations": [],
    "uuid": "f1c1708968e8a2ccfa2d1462c2aa8b32a5a5da46",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-merus-and-simcere-announce-strateg/brief-merus-and-simcere-announce-strategic-collaboration-on-multiple-bispecific-antibodies-idUSFWN1P30IT",
    "ord_in_thread": 0,
    "title": "BRIEF-Merus And Simcere Announce Strategic Collaboration On Multiple Bispecific Antibodies",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Simcere Pharmaceutical Group ( IPO-SMPT.HK ):\n* MERUS AND SIMCERE ANNOUNCE STRATEGIC COLLABORATION ON MULTIPLE BISPECIFIC ANTIBODIES\n* MERUS - AGREED TO GRANT SIMCERE EXCLUSIVE LICENSE TO DEVELOP & COMMERCIALIZE IN CHINA 3 BISPECIFIC ANTIBODIES USING COâ€˜S BICLONICS TECHNOLOGY PLATFORM\n* MERUS NV- CO TO BE ELIGIBLE TO GET UPFRONT & MILESTONE PAYMENTS CONTINGENT UPON SIMCERE ACHIEVING CERTAIN SPECIFIED DEVELOPMENT & COMMERCIAL GOALS\n* MERUS NV - MERUS WILL BE ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS ON SALES OF ANY PRODUCTS RESULTING FROM COLLABORATION IN CHINA FROM SIMCERE\n* MERUS NV - SIMCERE WILL BE ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS ON SALES OUTSIDE OF CHINA FROM MERUS\n* MERUS NV - ADDITIONAL FINANCIAL DETAILS WERE NOT DISCLOSED UNDER COLLABORATION WITH SIMCERE Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T20:08:00.000+02:00",
    "crawled": "2018-01-09T17:13:55.028+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "simcere",
        "pharmaceutical",
        "group",
        "merus",
        "simcere",
        "announce",
        "strategic",
        "collaboration",
        "multiple",
        "bispecific",
        "antibody",
        "merus",
        "agreed",
        "grant",
        "simcere",
        "exclusive",
        "license",
        "develop",
        "commercialize",
        "china",
        "bispecific",
        "antibody",
        "using",
        "co",
        "biclonics",
        "technology",
        "platform",
        "merus",
        "co",
        "eligible",
        "get",
        "upfront",
        "milestone",
        "payment",
        "contingent",
        "upon",
        "simcere",
        "achieving",
        "certain",
        "specified",
        "development",
        "commercial",
        "goal",
        "merus",
        "nv",
        "merus",
        "eligible",
        "receive",
        "tiered",
        "royalty",
        "payment",
        "sale",
        "product",
        "resulting",
        "collaboration",
        "china",
        "simcere",
        "merus",
        "nv",
        "simcere",
        "eligible",
        "receive",
        "tiered",
        "royalty",
        "payment",
        "sale",
        "outside",
        "china",
        "merus",
        "merus",
        "nv",
        "additional",
        "financial",
        "detail",
        "disclosed",
        "collaboration",
        "simcere",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}